Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 23–Aug 30, 2026)

· 1 min read

Here’s what’s on the biotech calendar for August 23–August 30: 2 FDA decision dates, 4 trial catalysts, and 1 earnings reports from tracked companies.

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-08-25 JAZZ — sBLA
2026-08-25 ZYME — adults with previously treated NDA

🧪 Trial Catalysts & Milestones

  • OSTX, 2026-08-26: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Registry

📊 Earnings This Week

  • ARTV, 2026-08-27 (est. EPS -0.64)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • ORIC: Phase 1, Phase 2, Recruiting in 9 days, score 60/100
  • SNDX: Phase 2, Active Trial in 9 days, score 60/100
  • CORT: Phase 2, Recruiting in 9 days, score 54/100

📈 Last Week’s Biggest Gainers

  • MRNA +176.97% (volume 26.9x average)
  • AMLX +63.84% (volume 14.1x average)
  • TWST +22.64% (volume 2.0x average)
  • BNTX +21.96% (volume 9.1x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.